Silverback Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Silverback Therapeutics, Inc.

Silverback Therapeutics, Inc. (ticker: SBTX) was a United States-listed biopharmaceutical company that traded on NASDAQ. The company was founded in Seattle in 2016 and was built around a proprietary platform called ImmunoTAC, designed to deliver therapeutics systemically while activating them locally at diseased tissue. For investors in Europe, Silverback was a classic clinical-stage biotech story: science-driven, R&D-intensive, and valued primarily on platform potential, pipeline execution, and the probability of generating differentiated clinical data rather than on commercial sales. The company’s core focus was oncology and other serious diseases where targeted delivery can improve efficacy and safety. Its lead program was SBT6050, described as a HER2-directed antibody conjugated to a TLR8 agonist payload, with initial development aimed at certain solid tumors such as breast, gastric, and non-small cell lung cancers. Silverback also worked on broader immunology-based approaches intended to unlock previously hard-to-address biological pathways. That positioned the company in a competitive field that includes other immuno-oncology developers, antibody-drug conjugate innovators, and targeted delivery platforms. From a market-position perspective, the investment case depended less on current revenue and more on scientific validation, preclinical and clinical readouts, tolerability, and capital access. In this segment, differentiation matters: investors typically assess whether a platform can show a meaningful therapeutic window, whether the mechanism is commercially relevant, and whether management can advance programs through expensive development stages. Silverback’s historical base in Seattle also placed it within one of the key U.S. biotech clusters, alongside a broader ecosystem of research, venture capital, and translational medicine. A crucial point for anyone reviewing SBTX today is corporate status. Silverback Therapeutics is no longer an independent operating public biotech under that name. In November 2022, it merged and changed its name to ARS Pharmaceuticals, meaning that “SBTX” is now mainly relevant as an historical ticker for legacy filings, including SEC Form 4 insider transaction analysis. For analysts, that means the name should be treated as a former clinical-stage biotech that has undergone a corporate transformation, rather than as a standalone listed company with an active independent operating profile today. This distinction is especially important when interpreting insider activity, historical news flow, and any legacy references to pipeline assets or business lines.